“After last month’s expiry of Indian exclusivity on the patent for semaglutide, the active ingredient in Ozempic and Wegovy, she expects even greater demand as the world’s largest producer of generic medicines also becomes a big consumer of weight-loss drugs…

Analysts at Nomura estimated Indian drugmakers could charge Rs3,500-Rs8,000 ($37-$85) a month for disposable pen injections, far lower than the Rs11,000-Rs16,000 for western branded versions.”

From Financial Times.